[UPI] A new blood test may be more than 80% accurate at identifying people at risk for developing Alzheimer's disease, a study presented Thursday during the Clinical Trials on Alzheimer's Disease conference in Boston found.
The test, called PrecivityAD and manufactured by St.Louis-based diagnostic company C2N, identifies those with elevated levels of the protein amyloid in the brain, the researchers said.
In people in the early stages of Alzheimer's disease, this protein accumulates in clusters in the brain called plaques, disrupting cognitive function.
These plaques, which form before the signs and symptoms of Alzheimer's disease appear, typically are identified through positron emission tomography, or PET, imaging scans of the brain. |